- The Core Definition: What Is a Contract Research Organization?
- What Does a CRO Actually Do?
- Medical Device CROs vs. Pharma CROs: Why the Distinction Matters
- Full-Service vs. Functional CROs
- The Regulatory Framework Behind CRO Engagements
- Why Geography Is a Strategic Variable for Device Startups
- What to Look for When Evaluating a CRO as a Device Startup
- How bioaccess® Fits This Framework
- Common Misconceptions About CROs
- FAQs
- The Bottom Line
If you're a MedTech founder preparing for your first clinical trial, the question "what is a contract research organization" tends to surface fast — usually right after your IDE gets approved or your Series A closes. A CRO is the external partner that moves your device from a bench-tested prototype to a submission-ready clinical evidence package. Choosing the right one is among the most consequential decisions you'll make before your next funding round.
This guide covers the essentials: what a CRO is, what it handles, how medical device CROs differ from pharma-focused ones, and what to look for when your timeline and runway aren't flexible.
The Core Definition: What Is a Contract Research Organization?
A contract research organization is a company that provides outsourced clinical research services to sponsors — the companies or institutions developing drugs, biologics, or medical devices. Sponsors hire CROs to design and execute clinical trials on their behalf, managing some or all of the operational, regulatory, and scientific work required to generate human safety and efficacy data.
The word "contract" matters here. A CRO works under a formal agreement with the sponsor, who retains ownership of the data and the regulatory submission. The CRO supplies the infrastructure, expertise, and execution capacity the sponsor doesn't have in-house.
For a 15-person MedTech startup, that usually means everything.
What Does a CRO Actually Do?
Scope varies widely depending on the CRO and the engagement model. At the full-service end, a CRO can manage:
- Regulatory strategy — Pre-Submission (Pre-Sub) meeting preparation, IDE or IND pathway alignment, and FDA interactions
- Protocol development — writing the clinical investigation plan, including endpoints, inclusion/exclusion criteria, and statistical analysis plan
- Site activation — identifying and qualifying clinical trial sites, training investigators, and executing site initiation visits
- Ethics and regulatory submissions — filing with Institutional Review Boards (IRBs) or ethics committees and national regulatory authorities
- Patient enrollment — recruitment strategy, screening, and consent processes
- Data management — building or deploying electronic data capture (EDC) systems, managing queries, and ensuring data integrity
- Safety monitoring — adverse event reporting, Data Safety Monitoring Board (DSMB) coordination, and protocol deviation management
- Biostatistics and clinical reporting — statistical analysis, clinical study reports (CSRs), and submission-ready documentation
At the narrower end, some CROs offer only regulatory consulting, only site management, or only data services. Knowing which model fits your program is worth clarifying before you issue an RFP.
Medical Device CROs vs. Pharma CROs: Why the Distinction Matters
Most CROs built their infrastructure around pharmaceutical drug trials. The regulatory frameworks are different. Drug trials follow FDA 21 CFR Parts 312 and 314; device trials follow 21 CFR Part 812. Protocol architecture for devices follows ISO 14155, not ICH E6 alone. Device-specific endpoints — often functional, anatomical, or procedural — require different site capabilities than pharmacokinetic endpoints.
A pharma CRO running a device trial isn't automatically equipped for it. Site staff need device-specific training. Investigators need procedural experience. The evidence package for a 510(k) or PMA looks nothing like an NDA.
This distinction is especially sharp for first-in-human (FIH) trials, where the primary goal is establishing initial safety and feasibility before scaling to a pivotal study. FIH device trials require sites with the right surgical or procedural infrastructure, investigators credentialed for the specific device category, and a regulatory pathway that accounts for IDE requirements from day one.
Full-Service vs. Functional CROs
Full-Service CROs
Full-service CROs manage the entire trial lifecycle under one contract. You hand off a protocol brief and receive a submission-ready evidence package. The advantage is single-point accountability — one team owns the timeline, the data, and the deliverable.
Large global CROs like ICON, Medpace, and PAREXEL operate at this scale. They're built for enterprise pharma and biotech clients running multi-site, multi-country studies with large teams and long timelines. For a Series A MedTech startup running a 15-patient FIH feasibility study, their overhead, minimum program sizes, and 18-to-24-month US or EU timelines often don't fit the reality of early-stage operations.
Functional Service Providers (FSPs)
FSPs provide specific functions — data management, regulatory writing, biostatistics — rather than end-to-end execution. They're useful when a sponsor has an internal clinical team that needs to fill a specific gap. When the sponsor has no clinical operations staff at all, an FSP arrangement typically creates more coordination burden than it solves.
Niche and Geography-Specific CROs
A third category focuses on a specific therapeutic area, device category, or geography. These CROs are often better fits for early-stage startups because their pricing, site networks, and regulatory relationships are calibrated for the programs they specialize in — not adapted from a pharma-first model.
The Regulatory Framework Behind CRO Engagements
When a CRO runs a trial outside the US on behalf of a US sponsor, the data still needs to meet FDA standards to be usable in a US submission. The relevant framework is FDA 21 CFR 812.28, which governs the acceptance of foreign clinical data for device IDE and IND submissions. Under this framework, trials conducted abroad must follow GCP standards consistent with ICH guidelines, and the data must be of sufficient quality to support the US submission.
This is why geography matters when choosing a CRO. A trial run in a jurisdiction with faster regulatory approvals can still generate FDA-bridgeable data — provided the CRO's compliance infrastructure is built for it.
Protocol architecture under ISO 14155, ICH-GCP operational standards, and data management that satisfies FDA audit expectations are non-negotiable regardless of where the trial runs.
Why Geography Is a Strategic Variable for Device Startups
US and EU regulatory timelines for ethics and site activation typically run six to twelve months. For a startup with 18 months of runway and a board milestone tied to first-in-human data, that window can consume more than half your available time before the first patient is even enrolled.
Latin America has become a structurally important geography for FIH device trials precisely because of this gap. In markets like Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are observed in 30 to 90 days. That's not a workaround — it reflects how those regulatory systems are structured, and the resulting data is accepted for US IDE and IND submissions under the same 21 CFR 812.28 framework.
Per-patient costs in Panama range from $12,000 to $22,000. US and EU cost structures for comparable programs run significantly higher across the board.
For a startup trying to generate a first safety and feasibility dataset before a Series B, the combination of faster approvals and lower per-patient costs can be the difference between hitting a milestone and missing it.
What to Look for When Evaluating a CRO as a Device Startup
1. Device-Specific Experience
Ask for case studies in your device category. A CRO that has run cardiovascular or neuromodulation FIH trials brings site relationships, investigator networks, and protocol templates that a general-purpose CRO simply doesn't have. Named case studies — not just logos on a slide — are a meaningful signal.
2. Regulatory Pathway Alignment
Your CRO should be able to advise on the IDE pathway, Pre-Sub meeting strategy, and how the evidence package from the trial maps to your next FDA submission. If they can't speak fluently to Pre-Sub preparation and IDE requirements, they're not the right fit for a device FIH program.
3. Single-Team Accountability
Fragmented vendor arrangements — one for protocol, another for sites, another for data — create coordination overhead that a small startup team can't absorb. A CRO that owns the full workstream from protocol to submission-ready package reduces the management burden on your side considerably.
4. Timeline Realism
Ask for a specific timeline from protocol finalization to first patient in. Ask what drives variability. A CRO that can't give you a structured answer hasn't run enough programs in the geography they're proposing.
5. Site Network Depth
Pre-qualified sites matter. A CRO that has to qualify new sites for every program adds months to the activation timeline. Ask how many sites are pre-qualified in the proposed geography and how recently they've been active.
6. Compliance Infrastructure
Confirm that the CRO operates under ICH-GCP standards, uses ISO 14155 protocol architecture for device trials, and has a compliance framework that satisfies FDA 21 CFR 812.28 for foreign data. ACRP certification and NCCA accreditation are additional signals of operational rigor.
How bioaccess® Fits This Framework
bioaccess® is a Miami-headquartered CRO that runs first-in-human and early-feasibility device trials across 19 Latin American and Caribbean markets. The FIH-12 program is a nine-workstream engagement covering FDA Pre-Sub and IDE/IND pathway alignment, protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package — with a 12-month timeline guarantee built into the program structure.
The site network includes 50-plus pre-qualified sites. Ethics and regulatory approvals in the operating jurisdictions are observed in 30 to 90 days. Data is collected under ISO 14155 and structured per FDA 21 CFR 812.28 for US IDE and IND submissions. Clinical operations are ACRP-certified under NCCA accreditation.
For device startups that are pre-clinical to IDE-ready and working against a funding milestone, the combination of Latin American regulatory speed, single-team accountability, and startup-accessible per-patient costs directly addresses the constraints that make US and EU CRO timelines impractical at the early stage.
Intake is capped at eight new programs per quarter — a reflection of the operational model, not a marketing tactic.
Common Misconceptions About CROs
"A CRO owns my data." No. The sponsor retains ownership of all clinical data and the regulatory submission. The CRO executes under contract.
"All CROs are interchangeable." They're not. The difference between a pharma-focused CRO and a device-focused one — or between a global enterprise CRO and a geography-specialized one — is significant in terms of site capabilities, regulatory expertise, and realistic timelines.
"Running a trial outside the US means the FDA won't accept the data." Not accurate. FDA 21 CFR 812.28 explicitly provides a framework for accepting foreign clinical data in device submissions, provided the trial meets GCP standards.
"A CRO handles the FDA submission." Most CROs deliver a submission-ready evidence package — the clinical study report, data tables, and supporting documentation. The sponsor (or their regulatory counsel) files the actual submission. Some CROs support the filing process; confirm scope explicitly before signing.
FAQs
What is a contract research organization in simple terms?
A contract research organization is a company that manages clinical trials on behalf of a sponsor. The sponsor — typically a MedTech or biopharma company — owns the device or drug and the resulting data. The CRO provides the operational, regulatory, and scientific infrastructure to run the trial.
How is a CRO different from a regulatory consultant?
A regulatory consultant advises on strategy — what pathway to take, how to prepare a Pre-Sub meeting, what the FDA will likely ask. A CRO executes the trial itself: protocol, sites, enrollment, data, and the final evidence package. Some CROs include regulatory strategy as part of their service; others don't.
Do medical device CROs and pharma CROs do the same thing?
They perform similar functions, but the regulatory frameworks, protocol standards, and site requirements differ. Device trials follow FDA 21 CFR Part 812 and ISO 14155; drug trials follow 21 CFR Part 312 and ICH E6. A CRO without device-specific experience may lack the site network and investigator relationships a device FIH trial requires.
Can a CRO run my trial outside the US and still generate FDA-accepted data?
Yes. FDA 21 CFR 812.28 provides the framework for accepting foreign clinical data in US device submissions, provided the trial is conducted under GCP standards. Latin American FIH trials structured under ISO 14155 and ICH-GCP are accepted for IDE and IND submissions.
How long does it take to start a clinical trial with a CRO?
In the US or EU, ethics and regulatory approvals typically take six to twelve months before the first patient can be enrolled. In Latin American markets like Panama, El Salvador, and Chile, those approvals are observed in 30 to 90 days — a meaningful compression of the pre-enrollment window.
What is a first-in-human trial, and why does it matter for a device startup?
A first-in-human trial is the initial study of a device or compound in human subjects, focused on establishing safety and initial feasibility. For a device startup, it's the milestone that generates the clinical evidence needed to support an IDE submission, attract Series B investors, or advance to a pivotal trial.
How do I know if a CRO is the right fit for my program?
Ask for case studies in your device category, a specific timeline from protocol to first patient in, and confirmation of their compliance framework — ICH-GCP, ISO 14155, FDA 21 CFR 812.28. A CRO that answers those questions with specifics rather than generalities has the operational experience to back it up.
The Bottom Line
A contract research organization is the operational partner that takes your device from a regulatory concept to a human dataset. For a MedTech startup, the CRO you choose largely determines whether you hit your next funding milestone or spend six months waiting on site activation in a geography that wasn't built for speed.
The right CRO for your program has device-specific experience, a compliance framework that satisfies FDA requirements for foreign data, a pre-qualified site network in a jurisdiction where approvals move quickly, and single-team accountability across the full workstream.
If you're 12 to 24 months from needing first-in-human data and want to understand what a structured FIH program looks like for your device, bioaccessla.com is a practical starting point.
Leave a Reply